Circulating Tumor DNA Harboring the<i>BRAF<sup>V600E</sup></i>Mutation May Predict Poor Outcomes of Primary Papillary Thyroid Cancer Patients

Sato, Ayaka; Tanabe, Masahiko; Tsuboi, Yoshikatsu; Niwa, Takashi; Shinozaki‐Ushiku, Aya; Seto, Yasuyuki; Murakami, Yoshinori

doi:10.1089/thy.2021.0267

Cited by 10 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can, instead, be used for follow-up after the identification of specific mutations in the tissue [ 121 ]. Sato [ 122 ], in a recent study on 22 cases of PTC, concluded that BRAF V600E, when detected in pre-surgery plasma is indicative of a high fraction of BRAF V600E in the tumor, and extrathyroidal extension. In addition, the presence of the mutation in post-surgery ctDNA can be predictive of tumor recurrence [ 122 ].…”

Section: Liquid Biopsymentioning

confidence: 99%

“…Sato [ 122 ], in a recent study on 22 cases of PTC, concluded that BRAF V600E, when detected in pre-surgery plasma is indicative of a high fraction of BRAF V600E in the tumor, and extrathyroidal extension. In addition, the presence of the mutation in post-surgery ctDNA can be predictive of tumor recurrence [ 122 ]. As advanced disease and dedifferentiated thyroid cancer are more likely to have detectable ctDNA, its analysis is particularly useful in this group of patients for diagnosis, deciding upon targeted therapy, and follow-up [ 123 , 124 ].…”

Section: Liquid Biopsymentioning

confidence: 99%

See 1 more Smart Citation

Emerging Biomarkers in Thyroid Practice and Research

Agarwal

Bychkov

Jung

2021

Cancers

View full text Add to dashboard Cite

Thyroid cancer is the most common endocrine malignancy. Recent developments in molecular biological techniques have led to a better understanding of the pathogenesis and clinical behavior of thyroid neoplasms. This has culminated in the updating of thyroid tumor classification, including the re-categorization of existing and introduction of new entities. In this review, we discuss various molecular biomarkers possessing diagnostic, prognostic, predictive and therapeutic roles in thyroid cancer. A comprehensive account of epigenetic dysregulation, including DNA methylation, the function of various microRNAs and long non-coding RNAs, germline mutations determining familial occurrence of medullary and non-medullary thyroid carcinoma, and single nucleotide polymorphisms predisposed to thyroid tumorigenesis has been provided. In addition to novel immunohistochemical markers, including those for neuroendocrine differentiation, and next-generation immunohistochemistry (BRAF V600E, RAS, TRK, and ALK), the relevance of well-established markers, such as Ki-67, in current clinical practice has also been discussed. A tumor microenvironment (PD-L1, CD markers) and its influence in predicting responses to immunotherapy in thyroid cancer and the expanding arena of techniques, including liquid biopsy based on circulating nucleic acids and plasma-derived exosomes as a non-invasive technique for patient management, are also summarized.

show abstract

Section: Liquid Biopsymentioning

confidence: 99%

Section: Liquid Biopsymentioning

confidence: 99%

Emerging Biomarkers in Thyroid Practice and Research

Agarwal

Bychkov

Jung

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…7 Sato et al indicated that the fractional abundance of mutated BRAF V600E in post-surgery ctDNA might predict PTC recurrence. 9 On the contrary, other studies reported that BRAF mutation may have no influence on the outcome of 131 I treatment in PTC patients. 19,28 In our study, BRAF mutation was detected in both tumor tissue and ctDNA in 1 patient with lung and bone metastases and 3 patients without distant metastasis.…”

Section: Discussionmentioning

confidence: 96%

“…Previous studies have found that BRAF mutation was associated with malignant progression of PTC and may be useful as a molecular biomarker for predicting the prognosis of PTC. [5][6][7][8][9][10] As a newly developed technology, liquid biopsy based on ctDNA has been widely used in the diagnosis and predicting prognosis in various tumors, such as lung cancer, breast cancer, colon cancer and anaplastic thyroid cancer. [11][12][13] ctDNA is single or double stranded DNA carrying the mutations of the original tumor released by tumor cells in the blood.…”

Section: Introductionmentioning

confidence: 99%

Preliminary Study on the Relationship of BRAF Mutations with the Outcome of the First 131I Radiotherapy and Malignant Biological Characteristics in Papillary Thyroid Carcinoma

Shangguan¹,

Zhang²,

Fang³

et al. 2021

IJGM

View full text Add to dashboard Cite

To investigate the relationship of BRAF mutation with the outcome of the first postoperative 131 I treatment and malignant biological characteristics in papillary thyroid carcinoma (PTC). Methods: Thirty-three patients with PTC who underwent their first 131 I treatment after total thyroidectomy were enrolled in this study. BRAF mutation in postoperative tumor tissue and circulating tumor DNA (ctDNA) in peripheral blood at the time of 131 I treatment were detected. According to the status of BRAF mutation, all patients were divided into 2 groups in each category of tumor tissues and ctDNA, respectively: 1) BRAF mutation, 2) BRAF wild-type. The Fisher's exact test was performed to analyze the relationship of BRAF mutation in either tumor tissue or ctDNA with the outcome of the first 131 I treatment and malignant characteristics of PTC. Results: BRAF mutation was detected in tumor tissues in 25 patients (25/33,75.8%), and all the patients had single mutation site. In ctDNA, BRAF mutation was detected in 5 patients (5/33, 15.2%), and all the patients had single mutation site. In both tumor tissues and ctDNA, BRAF mutation showed no relationship with the outcome of first 131 I treatment and the malignant biological characteristics (P>0.05). Conclusion:The value of BRAF mutation alone might be limited in predicting therapeutic outcome of the first 131 I treatment in PTC. No definitive relevance was found between BRAF mutation and malignant biological features in PTC.

show abstract

“…The majority of studies analyzing cfDNA in thyroid cancer are still based on qPCR [ 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 ]. However, in recent years, many papers applied NGS [ 45 , 46 , 47 , 48 ] and the dPCR [ 42 , 46 , 49 , 50 , 51 , 52 , 53 ].…”

Section: Cfdna Analysis In Thyroid Cancersmentioning

confidence: 99%

Cell-Free DNA Analysis within the Challenges of Thyroid Cancer Management

Marotta

Cennamo

Civita

et al. 2022

Cancers

View full text Add to dashboard Cite

Thyroid cancer is the most frequent endocrine malignancy with an increasing incidence trend during the past forty years and a concomitant rise in cancer-related mortality. The circulating cell-free DNA (cfDNA) analysis is a patient’s friendly and repeatable procedure allowing to obtain surrogate information about the genetics and epigenetics of the tumor. The aim of the present review was to address the suitability of cfDNA testing in different forms of thyroid cancer, and the potential clinical applications, as referred to the clinical weaknesses. Despite being limited by the absence of standardization and by reproducibility and validity issues, cfDNA assessment has great potential for the improvement of thyroid cancer management. cfDNA may support the pre-surgical definition of thyroid nodules by complementing invasive thyroid fine needle aspiration cytology. In addition, it may empower risk stratification and could be used as a biomarker for monitoring the post-surgical disease status, both during active surveillance and in the case of anti-tumor treatment.

show abstract

Circulating Tumor DNA Harboring theBRAF^V600EMutation May Predict Poor Outcomes of Primary Papillary Thyroid Cancer Patients

Cited by 10 publications

References 21 publications

Emerging Biomarkers in Thyroid Practice and Research

Emerging Biomarkers in Thyroid Practice and Research

Preliminary Study on the Relationship of BRAF Mutations with the Outcome of the First 131I Radiotherapy and Malignant Biological Characteristics in Papillary Thyroid Carcinoma

Cell-Free DNA Analysis within the Challenges of Thyroid Cancer Management

Contact Info

Product

Resources

About

Circulating Tumor DNA Harboring theBRAFV600EMutation May Predict Poor Outcomes of Primary Papillary Thyroid Cancer Patients

Cited by 10 publications

References 21 publications

Emerging Biomarkers in Thyroid Practice and Research

Emerging Biomarkers in Thyroid Practice and Research

Preliminary Study on the Relationship of BRAF Mutations with the Outcome of the First 131I Radiotherapy and Malignant Biological Characteristics in Papillary Thyroid Carcinoma

Cell-Free DNA Analysis within the Challenges of Thyroid Cancer Management

Contact Info

Product

Resources

About

Circulating Tumor DNA Harboring theBRAF^V600EMutation May Predict Poor Outcomes of Primary Papillary Thyroid Cancer Patients